This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Peptidomimetics designed to bind to RAS effector domain are promising cancer therapeutic compounds
Scientific Reports Open Access 22 September 2022
-
A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer
Scientific Reports Open Access 24 January 2019
-
Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
Nature Communications Open Access 19 May 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Thompson, H. US National Cancer Institute's new Ras project targets an old foe. Nat Med 19, 949–950 (2013). https://doi.org/10.1038/nm0813-949
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm0813-949
This article is cited by
-
Peptidomimetics designed to bind to RAS effector domain are promising cancer therapeutic compounds
Scientific Reports (2022)
-
EPHA2 feedback activation limits the response to PDEδ inhibition in KRAS-dependent cancer cells
Acta Pharmacologica Sinica (2020)
-
Comparison of Native Aspirates and Cytological Smears Obtained by EUS-Guided Biopsies for Effective DNA/RNA Marker Testing in Pancreatic Cancer
Pathology & Oncology Research (2020)
-
A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer
Scientific Reports (2019)
-
Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
Nature Communications (2016)